Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;50(5):317-319.
doi: 10.1097/OLQ.0000000000001769. Epub 2023 Jan 13.

Predominance of High-Level Tetracycline-Resistant Neisseria gonorrhoeae in Kenya: Implications for Global Implementation of Doxycycline Postexposure Prophylaxis for Prevention of Sexually Transmitted Infections

Olusegun O Soge, Rodal Issema  1 , Elizabeth Bukusi, Jared M Baeten  2 , Andrew Mujugira, Connie Celum, R Scott McClelland, Jenell Stewart; Partners PrEP Study Team
Affiliations

Predominance of High-Level Tetracycline-Resistant Neisseria gonorrhoeae in Kenya: Implications for Global Implementation of Doxycycline Postexposure Prophylaxis for Prevention of Sexually Transmitted Infections

Olusegun O Soge et al. Sex Transm Dis. .

Abstract

Using archived Neisseria gonorrhoeae samples from 2008 to 2012, the prevalence of tet (M) genemediating high-level tetracycline resistance in N. gonorrhoeae was 96% among 50 Kenyan women. Determining the local and national prevalence of gonococcal tetracycline resistance and surveillance of gonococcal antimicrobial resistance can inform the implementation of doxycycline postexposure prophylaxis for STI prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest and Sources of Funding: Dr. Soge has received research funding outside the submitted work, awarded to the University of Washington, from Hologic Inc. and SpeeDx. Dr. Baeten is an employee of Gilead Sciences outside of the submitted work. Dr. McClelland has received honoraria for consulting for Lupin Pharmaceuticals and research funding, paid to the University of Washington, from Hologic Corporation. All other coauthors do not have any declared conflict of interest.

References

    1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact: web annex 2: data methods Available at https://www.who.int/publications/i/item/9789240027077. Accessed November 5, 2022.
    1. Whittles LK, Didelot X, White PJ. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. Lancet Infect Dis 2022; 22(7):1030–1041. - PMC - PubMed
    1. Otieno FO, Ndivo R, Oswago S, et al. Evaluation of syndromic management of sexually transmitted infections within the Kisumu Incidence Cohort Study. Int J STD AIDS 2014; 25(12):851–859. - PMC - PubMed
    1. Stewart J, Bukusi E, Celum C, et al. Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention. AIDS 2020; 34(5):651–658. - PMC - PubMed
    1. Molina JM, Charreau I, Chidiac C et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18(3):308–317. - PubMed

Publication types

MeSH terms